Journal Article

Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial

Makatsoris, Thomas, Aravantinos, Gerasimos, Pectasides, Dimitrios, Gourgioti, Georgia, Varthalitis, Ioannis, Papaxoinis, George, Wirtz, Ralph M., Vrettou, Eleni, Karavasilis, Vasilios, Gakou, Chryssa, Fountzilas, George, Syrigos, Konstantinos N., Rallis, Grigorios, Lazaridis, Georgios, Bournakis, Evangelos, Raptou, Georgia, Kalogeras, Konstantine T., Pentheroudakis, George, Kotoula, Vassiliki, Galani, Eleni

2015

Overview

Although host immune response is an emerging prognostic factor for colorectal cancer, there is no consensus on the optimal methodology, surrogate markers or tissue for study. Tumour blocks were prospectively collected from 344 patients with stage II/III colorectal cancer (CRC) treated with adjuvant chemotherapy. Whole section lymphocytic infiltration was studied along with mRNA expression of CD3Z, CD8, CD4, CXCL9, CXCL13, IGHM, FOXP3, SNAI2 and ESR1 by qRT-qPCR in tissue microarray (TMA) cores from the centre of tumour, invasive margin and adjacent normal mucosa. Lymphocytic infiltration, deficient MMR (10.9%), KRAS (40.7%) and BRAF (4.9%) mutations or single mRNA gene expression were not prognostic. Tumour ESR1 gene expression (Hazard Ratio [HR] for relapse 2.33, 95% CI 1.35-4.02; HR for death 1.74, 95% CI 1.02-2.97) and absence of necrosis (HR for relapse 1.71, 95% CI 1.05-2.71; HR for death 1.98, 95% CI 1.14-3.43) were adverse prognostic features. We used CD3Z and CD8 expression in order to devise the mRNA-based Immune Score (mIS) and proceeded to partitioning analysis in 267 patients, with age, stage, tumour site (Right vs Left CRC), KRAS mutation and tumour mIS as input factors. Only in patients with stage III right-sided colon cancer, a low immune response was associated with inferior disease-free survival (mIS-low, HR for relapse 2.28, 95% CI 1.05-8.02). No prognostic significance was seen for tumour mIS in any other stage or site of CRC, or for a similar mIS score derived from adjacent normal mucosa. Independent adverse prognostic significance was retained in multivariable analysis for absence of necrosis, tumour ESR1 expression in all patients and low tumour mIS in stage III right-sided CRC. In localised CRC, mRNA-based CD3Z/CD8 profiling of tumour immune response may have stage, site and tissue-specific prognostic significance, along with ESR1 expression. ANZCTR.org.au ACTRN12610000509066.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Adenocarcinoma - diagnosis / Adenocarcinoma - genetics / Adenocarcinoma - immunology / Adenocarcinoma - mortality / Adult / Age Factors / Aged / Analysis / Antigens, CD - genetics / Antigens, CD - immunology / Cancer / Care and treatment / CD4 antigen / CD8 antigen / Chemokines, CXC - genetics / Chemokines, CXC - immunology / Chemotherapy / Colon / Colon cancer / Colorectal cancer / Colorectal carcinoma / Colorectal Neoplasms - diagnosis / Colorectal Neoplasms - genetics / Colorectal Neoplasms - immunology / Colorectal Neoplasms - mortality / Cores / CXCL13 protein / DNA methylation / DNA microarrays / ESR1 protein / Estrogen Receptor alpha - genetics / Estrogen Receptor alpha - immunology / Female / Foxp3 protein / Gene expression / Gene Expression Profiling / Gene Expression Regulation, Neoplastic / Genetic aspects / Heterozygote / Hospitals / Humans / Immune response / Immune system / Immunity, Innate / Infiltration / Internal medicine / Invasiveness / K-Ras protein / Laboratories / Localization / Lymphatic Metastasis / Male / Medical prognosis / Medical research / Medicine / Metastases / Middle Aged / Mucosa / Mutation / Necrosis / Neoplasm Proteins - genetics / Neoplasm Proteins - immunology / Neoplasm Staging / Oncology / Pathology / Patients / Prognosis / Prospective Studies / Retrospective Studies / Snail protein / Survival Analysis / Tissue Array Analysis / Transcription Factors - genetics / Transcription Factors - immunology / Tumors